Alkem Laboratories Ltd
NSE:ALKEM

Watchlist Manager
Alkem Laboratories Ltd Logo
Alkem Laboratories Ltd
NSE:ALKEM
Watchlist
Price: 5 675.5 INR 0.29% Market Closed
Market Cap: 678.6B INR

Alkem Laboratories Ltd
Net Income (Common)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Alkem Laboratories Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
Alkem Laboratories Ltd
NSE:ALKEM
Net Income (Common)
₹23.6B
CAGR 3-Years
29%
CAGR 5-Years
10%
CAGR 10-Years
12%
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Net Income (Common)
₹57.7B
CAGR 3-Years
23%
CAGR 5-Years
29%
CAGR 10-Years
15%
Cipla Ltd
NSE:CIPLA
Net Income (Common)
₹54.4B
CAGR 3-Years
28%
CAGR 5-Years
24%
CAGR 10-Years
12%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Net Income (Common)
₹104.5B
CAGR 3-Years
37%
CAGR 5-Years
48%
CAGR 10-Years
14%
Lupin Ltd
NSE:LUPIN
Net Income (Common)
₹43.2B
CAGR 3-Years
299%
CAGR 5-Years
N/A
CAGR 10-Years
7%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Net Income (Common)
₹21.4B
CAGR 3-Years
39%
CAGR 5-Years
12%
CAGR 10-Years
4%
No Stocks Found

Alkem Laboratories Ltd
Glance View

Alkem Laboratories Ltd., founded in 1973, has emerged as a significant player in India's pharmaceutical landscape, deftly combining innovation with a robust distribution network. Anchored in Mumbai, Alkem began as a modest venture but quickly evolved into a powerhouse, renowned for manufacturing a broad spectrum of branded generics, over-the-counter products, and active pharmaceutical ingredients (APIs). The company's success lies in its ability to cater to both domestic and international markets, primarily thriving on the ever-increasing demand for affordable healthcare solutions. Its formidable market presence in India is supported by a strong sales force and an extensive distribution network, ensuring its therapies reach even the most remote corners of the country. Internationally, Alkem has carved a niche for itself, with the United States being one of its major export markets. It strategically entered this competitive arena, building a portfolio of ANDAs (Abbreviated New Drug Applications) that allowed it to provide lower-cost alternatives to big pharma's patented drugs. This not only fueled its revenue growth but also fortified its standing as a go-to source for quality generics. Alkem's research and development efforts underpin its commitment to healthcare innovation, as it constantly seeks to expand its therapeutic repertoire. By consistently focusing on quality, affordability, and resourceful adaptation to global healthcare needs, Alkem Laboratories Ltd. has managed to script a growth story that is both impressive and sustainable.

ALKEM Intrinsic Value
HIDDEN
Show

See Also

What is Alkem Laboratories Ltd's Net Income (Common)?
Net Income (Common)
23.6B INR

Based on the financial report for Sep 30, 2025, Alkem Laboratories Ltd's Net Income (Common) amounts to 23.6B INR.

What is Alkem Laboratories Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
12%

Over the last year, the Net Income (Common) growth was 11%. The average annual Net Income (Common) growth rates for Alkem Laboratories Ltd have been 29% over the past three years , 10% over the past five years , and 12% over the past ten years .

Back to Top